Skip to main content
Equibles
AMGN logo

AMGN · Amgen Inc

Track AMGN — free

Use AMGN with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research AMGN.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$465.67 -1.39 (-0.30%) At close · Nov 13
S&P 500 member Nasdaq-100 member Russell 1000 member Dow 30 member Rebalance outlook locked
Market Cap
$251.89B
Shares
540.91M
Volume · Nov 13 2.12M Avg daily vol (3M) 2.79M

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$465.67 Open$467.53 Day$462.22–468.00 52W close$313.85–478.48 Avg vol 30d2.7M Short int12.6M · 2.3% of shares · 5.0d Short vol49% Last earningsNov 3, 2026 DataJan 2020–Nov 2026 Filing10-Q · Nov 4

Up next

Next earnings call
Feb 2, 2027 Est · unconfirmed · in 11 wks
Q3 2026 earnings call transcript
call held Nov 3, 2026
Play latest call

Latest documents

2026
Nov 4
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Revenues rise 8%, net income climbs 20%

Amgen reported total revenues of $10,365 million and net income of $3,864 million, up 8% and 20%. TEZSPIRE and IMDELLTRA/IMDYLLTRA delivered positive Phase 3 results.

Revenue $10.37B ▲ 8.5% Net income $3.86B ▲ 20.1% Diluted EPS $7.08 ▲ 19.4%
Read from the MD&A section
5 source passages
Amgen operates in one operating segment: human therapeutics. Total revenues | 10,365 | 9,557 | 8% | 29,037 | 26,885 | 8% Net income | 3,864 | 3,216 | 20% | 8,058 | 6,378 | 26% In August 2026, we and our collaboration partner AstraZeneca announced positive top-line results from the Phase 3 CROSSING trial of TEZSPIRE in patients living with eosinophilic esophagitis (EoE). In September 2026, we announced results from the Phase 3 DeLLphi-305 study, which met its primary endpoint at a pre-specified interim analysis, demonstrating a statistically significant and clinically meaningful improvement in overall survival with IMDELLTRA/IMDYLLTRA in combination with AstraZeneca’s IMFINZI® (durvalumab) compared to IMFINZI alone. Open the document at this passage
Nov 3
Current report 8-K
Revenue rose 8% as GAAP EPS reached $7.08

Amgen reported that third quarter of 2026 revenue rose 8% to $10.4 billion and GAAP EPS increased 19% from $5.93 to $7.08, while non-GAAP EPS increased 14% to $6.45. Full year 2026 revenue guidance is $38.9 billion to $39.7 billion.

Financial results Read from the first part of this long document
5 source passages
Amgen (NASDAQ:AMGN) today announced financial results for the third quarter of 2026. For the third quarter, total revenues increased 8% to $10.4 billion in comparison to the third quarter of 2025. GAAP earnings per share (EPS) increased 19% from $5.93 to $7.08 for the third quarter, driven by higher revenues. Non-GAAP EPS increased 14% from $5.64 to $6.45 for the third quarter, primarily driven by higher revenues, partially offset by higher operating expenses. Total revenues in the range of $38.9 billion to $39.7 billion. Open the document at this passage
Oct 27
Current report 8-K Events of Oct 26
Director or officer change, or executive pay

Amgen Inc. appointed David W. Gibbs to its Board of Directors on October 26, 2026, effective immediately, and to its Audit Committee and Compensation and Management Development Committee. The Board now has 13 directors, 12 of whom are independent.

All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$38.90B
Trailing 12 months
Net income (TTM)
$9.39B
Trailing 12 months
Revenue growth YoY
+8.5%
Year over year
Operating margin
32.4%
Trailing 12 months
P / E (TTM)
27.0
Trailing earnings · reciprocal yield 3.7%
FCF yield
3.8%
TTM · current market cap
Return on invested capital
19.4%
Trailing 12 months
Net cash
−$40.82B
Latest balance sheet
Dividend yield
2.1%
Trailing 12 months
Shares change YoY
+0.7%
Year over year · more shares
Price change (1Y)
+38.6%
Trailing year
Short interest
2.3%
Latest settlement · 5.0 days to cover
View all 125 metrics

Quarterly results

Revenue Net income Net loss
▲10.9% $9.09B $627.00M '24 Q4* ▲9.4% $8.15B $1.73B '25 Q1 ▲9.4% $9.18B $1.43B '25 Q2 ▲12.4% $9.56B $3.22B '25 Q3 ▲8.6% $9.87B $1.33B '25 Q4* ▲5.8% $8.62B $1.82B '26 Q1 ▲9.5% $10.05B $2.38B '26 Q2 LATEST ▲8.5% $10.37B $3.86B '26 Q3

* Q4 derived as the full year minus Q1 to Q3.

AI Brief

Q3 FY26 earnings call · Nov 3, 2026
Q3 FY26

TL;DR. Amgen raised 2026 revenue and non-GAAP EPS guidance after third-quarter revenue grew 8% and both GAAP and non-GAAP EPS increased; its six key growth drivers grew 27%, and pipeline updates included positive Phase III readouts and MariTide Phase III progress. Risks included biosimilar-driven product declines, higher third- and fourth-quarter expense pressure, lower free cash flow, TAVNEOS regulatory uncertainty and FDA clinical holds.

Bullish
  • + Amgen raised its 2026 revenue and non-GAAP EPS guidance ranges.
  • + The six key growth drivers grew 27% year over year and represented more than 70% of product sales.
  • + IMDELLTRA's Phase 3 first-line maintenance trial significantly improved overall survival and progression-free survival.
  • + TEZSPIRE met both co-primary endpoints in Phase 3 eosinophilic esophagitis, with benefits sustained through week 52.
Bearish
  • − Free cash flow declined to $3.7 billion from $4.2 billion in the prior-year quarter.
  • − Fourth-quarter operating expenses are expected to increase sequentially, including cost of sales and SG&A.
  • − Third-quarter non-GAAP operating expenses and cost of sales as a percentage of product sales increased.

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Buy
SellHoldBuy
Technical Buy Momentum Very Strong Sentiment Bullish Fundamentals Excellent Quant / Vol Moderate
Market backdrop VIX 19.3 · elevated Equity put/call 0.63
Technical
price trend
Buy
50 / 200-day cross No cross
Price vs 200-day avg +22%
above
Price vs 50-day avg +9%
above
RSI (14) 62
neutral
MACD trend Negative
52-week position 92%
near high
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Strong
1-month return +8%
trailing
6-month return +39%
trailing
YTD return +42%
this year
Relative strength +38%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $425 › 200d $381 — 50d above 200d
Institutional flow Accumulating
3,000 of 3,190 funds reported for Sep 30 · net +1.5M sh shares · +203 new
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
2.33% of shares out · ▼ -5.9% MoM · 5.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
3,190 holders — near 3-yr high, broad support
Squeeze score 62
elevated · 0–100
Fundamentals
Excellent
Revenue growth +9%
Y/Y
EPS growth +88%
Y/Y
Free cash flow $8.1B
Valuation P/E 27
below peers
Buyback $6.8B
remaining
Balance sheet $45.5B
net debt
Quant / Vol
risk profile
Moderate
Volatility 29%
annualized · 1-yr
Max drawdown −17%
past year
ATR 2.5%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Beat or met 8 of last 8
Latest guidance · from the 8-K filed Aug 4, 2026
Total revenues · full year 2026 Raised $38.2B – $39.4B
Apr 30, 2026 $37.1B – $38.5B changed to Aug 4, 2026 $38.2B – $39.4B
prior FY $36.75B midpoint +5.6% Y/Y
GAAP EPS · full year 2026 Raised $15.80 – $17.08
Apr 30, 2026 $15.62 – $17.10 changed to Aug 4, 2026 $15.80 – $17.08
prior FY $14.23 midpoint +15.5% Y/Y
Non-GAAP EPS · full year 2026 Raised $22.30 – $23.50
Apr 30, 2026 $21.70 – $23.10 changed to Aug 4, 2026 $22.30 – $23.50
GAAP tax rate · full year 2026 Maintained 14.5% – 16%
Apr 30, 2026 14.5% – 16% changed to Aug 4, 2026 14.5% – 16%
Non-GAAP tax rate · full year 2026 Maintained 15% – 16.5%
Apr 30, 2026 15% – 16.5% changed to Aug 4, 2026 15% – 16.5%
Capital expenditures · full year 2026 Maintained $2.6B
Apr 30, 2026 $2.6B changed to Aug 4, 2026 $2.6B
Share repurchases · full year 2026 up to $3B
Guided vs delivered · last 8 settled
Total revenues 2025
guided $35.8B – $36.6B
$36.75B Beat +1.5%
GAAP diluted EPS guidance Year Ending December 31, 2025
guided $13.76 – $14.60
$14.23 In line
Total revenues full year 2024
guided $32.8B – $33.8B
$33.42B In line
EPS full year 2024
guided $6.57 – $7.62
$7.56 In line

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Buy
1 · 3 · 3
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+22% Bullish
Price vs 50-day avg
+9% Bullish
RSI (14)
62 Neutral
MACD trend
Negative Bearish
52-week position
92% Bullish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross) No cross
50d $425 › 200d $381 — 50d above 200d
Institutional flow Accumulating
3,000 of 3,190 funds reported for Sep 30 · net +1.5M sh shares · +203 new
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
2.33% of shares out · ▼ -5.9% MoM · 5.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
3,190 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $314 Now $466 · 92% Range high $478
vs 200-day avg +22% vs 50-day avg +9%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
AMJEVITA/AMGEVITA sales 155M the second quarter —
Biosimilars total sales 199M Q2 '26 —
BLINCYTO sales 472M the second quarter —
Enbrel sales 580M the second quarter —
Established products sales 632M the second quarter —
EVENITY sales 714M the second quarter —
Free Cash Flow 3.5B the second quarter of 2026 —
IMDELLTRA/IMDYLLTRA sales 288M the second quarter —
KRYSTEXXA sales 400M the second quarter —
KYPROLIS sales 314M the second quarter —
LUMAKRAS/LUMYKRAS sales 111M the second quarter —
MVASI sales 153M the second quarter —
Non-GAAP diluted EPS non-GAAP $6.29 Three months ended June 30, 2026 —
Non-GAAP net income non-GAAP $3.42B Three months ended June 30, 2026 —
GAAP → non-GAAP reconciliation
GAAP GAAP net income 2.38B
+1.08B Adjustments to income before income taxes, net of the income tax effect
-32M Other income tax adjustments
= Non-GAAP net income 3.42B
Non-GAAP operating income non-GAAP 4.6B the second quarter —
GAAP → non-GAAP reconciliation
GAAP GAAP operating income 3.51B
+1.1B Adjustments to operating expenses
= Non-GAAP operating income 4.61B
Non-GAAP operating margin non-GAAP 48.4% the second quarter —
Nplate sales 430M the second quarter —
Operating Margin (operating income as % of product sales, GAAP) 36.8% Q2 ’26 —
Operating Margin (operating income as % of product sales, non-GAAP) non-GAAP 48.4% the second quarter —
Otezla sales 491M the second quarter —
PAVBLU sales 287M the second quarter —
Prolia sales 759M the second quarter —
Repatha sales 953M the second quarter —
Six key growth drivers year-over-year growth 26% the second quarter —
TAVNEOS sales 150M the second quarter —
TEPEZZA sales 576M the second quarter —
TEZSPIRE sales 486M the second quarter —
UPLIZNA sales 335M the second quarter —
Vectibix sales 338M the second quarter —
XGEVA sales 352M the second quarter —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Drug Manufacturers - General — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
AMGN
Amgen Inc
this stock
$251.89B +42.3% +8.8% 27.0 2.3%
LLY
ELI LILLY & Co
 $1.36T +34.3% +44.7% 46.9 0.8%
JNJ
Johnson & Johnson
 $687.89B +38.1% +6.0% 43.4 0.7%
ABBV
AbbVie Inc.
 $521.50B +29.1% +8.6% 50.8 0.9%
MRK
Merck & Co., Inc.
 $364.26B +40.4% +1.3% 152.3 1.1%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
3,331
% held
84.7%
Reported
3,000 of 3,190
Top holder
BlackRock, Inc.
Held Float
View
Held by Funds
Fund positions
1,239
View
Short & Settlement
Short Interest Falling
Shares short
12.6M
Days to cover
5.0d
Change
-785.9K sh
View
Short Volume
Short vol %
49%
As of
Nov 13, 2026
Short Total
View
Fails to Deliver
FTD shares
447
Value
$186.7K
As of
Oct 13, 2026
View
Off-Exchange
Off-exchange %
47.2%
Week of
Oct 5, 2026
Off-exch Lit
View
Smart Money
Congressional Trades Sell
Member
David J. Taylor
Amount
$1.0K–$15.0K
Traded
Nov 3, 2026
View
Financials
Financials
Revenue (FY)
$36.8B
Net income (FY)
$7.7B
EPS diluted
$14.23
View
Buybacks
Remaining
$6.8B
View
Filings
SEC Filings
Latest
10-Q
Filed
Nov 4, 2026
This year
23

Amgen reported total revenues of $10,365 million and net income of $3,864 million, up 8% and 20%. TEZSPIRE and IMDELLTRA/IMDYLLTRA delivered positive Phase 3 results.

View
Proposed Sales
Value
$516.8K
Shares
1.3K
Filed
Aug 13, 2026
View
Earnings & Events
Webcasts
Last webcast
Nov 3, 2026
View
Investor Relations
Latest news
AMGEN ANNOUNCES WEBCAST OF 2026 T…
Published
Oct 28, 2026
View

Performance

5D 20D 120D MTD YTD
AMGN +1.1% +7.7% +38.6% -0.1% +42.3%
SPY +2.6% -1.2% +0.5% -0.2% +10.6%
vs SPY -1.5% +8.8% +38.1% +0.1% +31.7%

Capital returns

Latest dividend
$2.52 / share · ex Aug 21, 2026
Declared · upcoming
$2.52 / share · ex Nov 20, 2026
Raised 5.9%
Paid (TTM)
$9.94 / share · 4 payouts
Dividend yield (TTM, derived)
2.13%
Full dividend history
Buyback program · as of Sep 30, 2026
Authorized
—
Spent (derived)
—
Remaining
$6.80B

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 318154 CUSIP 031162100 13F (30d) 2574 filings 2445 filers Visit website Investor relations